Pharma Integrates 2023 Track 2
Big Health Issues and Enablers
How do we tackle some of the biggest health challenges, such as chronic conditions, respiratory and cancer?
How do we enable a better Industry, through creating diverse skilled teams, empowering the patient and navigating the economic and regulatory environment?
Welcome and Fireside Chat
Pharma CEO Plenary Discussion: View from the top – navigating the opportunities and challenges presented by a dynamic UK environment and achieving success.
Susan Rienow | Country President UK, Pfizer | President, ABPI
Marie-Andrée Gamache | Country President | Novartis UK and Ireland
Dr Antonio Payano | Chief Executive Officer | Bayer UK & Ireland
Tamsin Berry | Head of Policy and Partnerships, AreteiaTx | Partner, Population Health Partners
Session 1: Panel Discussion followed by Q&A
Have a little ‘patients’
The patient voice is getting louder in all aspects of healthcare, from self-diagnosis to policy discussion and clinical trial design. What more can be done to engage patient groups and put patients at the centre of their healthcare journey?
Kathryn Simpson | Business Consultant | Kathryn Simpson Consulting Limited
Charlotte Harris | Head of Front End Innovation | Team Consulting
Oleksandr Gorbenko | Global Patient Affairs Director | Ipsen
Catherine Kettleborough | Translational Challenge Leader | LifeArc
Abigail Epstein | Head of Communications and Patient Advocacy | Takeda
Session 2: Panel Discussion followed by Q&A
Britain’s got talent?
As our ability to treat diseases becomes ever more advanced, the skills gap across the pharmaceutical sector continues to grow. How can we upskill our workforce, better manage talent, and encourage diversity to drive innovation?
Jane Kennedy | Chief Business Officer | Discovery Park
Fiona Marston | Chair & Chief Executive Officer | Erebagen
Nick Smith | Regional Operations Manager | Scitech
Amina Udechuku | Head of Vaccines, UK | Takeda UK
Andrew Croydon | Director, Education and Examination Policy & Partnerships | The ABPI
Session 3: Panel Discussion followed by Q&A
From ‘sick care’ to ‘health care’
With NHS demand outstripping capacity, we must focus on preventative healthcare. How can we turn a ‘sick care’ service into a ‘health care’ service that supports a healthier and wealthier nation?
John Deanfield CBE | Professor of Cardiology | University College London
Marcel Gehrung | Chief Executive Officer and Co-Founder | Cyted
Cedi Frederick | Chair | NHS Kent and Medway
Tamsin Berry | Partner & Head of Policy and Partnerships | AreteiaTx & Population Health Partners
Sir Keith Mills GBE DL | Chairman | Camelot
Session 4: Panel Discussion followed by Q&A
Trialling a new approach to clinical trials
Adaptive trials, decentralised trials, virtual trials … many new clinical trials models are appearing on the scene. How can the UK deliver more innovative trials across the board to make the most of assets within the NHS?
Lord James O’Shaughnessy | Senior Partner | Newmarket Strategy
James Chennells | Head Exploration & Discovery R&D Data Science & Artificial Intelligence | Bayer
Paul Wicks | Independent Consultant | Wicks Digital Health
Miranda Mapleton | Chief Executive Officer | White Swan
Nina Skorytchenko | Co-founder & Chief Executive Officer | Avenna
Session 5: Panel Discussion followed by Q&A
But does it sell?
Regulatory and commercialisation strategies can make or break the success of new treatments. How can we streamline processes to accelerate market access and deliver ‘value’?
Martino Picardo | Chairman | Discovery Park
Suzanne Dilly | Chief Executive Officer | ValiRx PLC
Camilla Easter | Chief Executive Officer | Oxford Medical Products
Hilary Mills-Baker | European Quality and Validation Manager | Emerson
Andrew Webb | Chief Executive Officer | Extruded Pharmaceuticals